Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.34 |
| ▸ | USP14 | P54578 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3962109 | 0.89 | PTGDR2 (0.39) | ALDH1A1KDM4ELMNATSHRHSD17B10 | |
| SCHEMBL3568659 | 0.88 | PTGDR2 (0.43) | PTGDR2 | |
| SCHEMBL3972653 | 0.82 | PTGDR2 (0.42) | ALDH1A1MAPTPTGDR2USP14 | |
| SCHEMBL2769893 | 0.82 | PTGDR2 (0.44) | ALDH1A1KDM4ELMNATSHRHSD17B10 | |
| SCHEMBL3968252 | 0.81 | PTGDR2 (0.38) | ALDH1A1MAPTPTGDR2USP14 | |
| SCHEMBL3969315 | 0.81 | P2RX3 (0.36) | ALDH1A1KDM4EMAPTTDP1PTGDR2 | |
| SCHEMBL3968885 | 0.81 | PPME1 (0.37) | ALDH1A1MAPTTDP1PTGDR2 | |
| SCHEMBL3965620 | 0.79 | PTGDR2 (0.54) | PTGDR2 | |
| SCHEMBL4636239 | 0.79 | PTGDR2 (0.35) | ALDH1A1MAPTTDP1PTGDR2USP14 | |
| SCHEMBL4635980 | 0.79 | L3MBTL1 (0.40) | ALDH1A1KDM4ELMNATSHRHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| EP-2094266-A1 | CRTH2 ANTAGONISTS | Argenta Discovery Limited (GB) | 2009-09-02 | — | — | EP | disclosed |
| WO-2008074966-A1 | CRTH2 ANTAGONISTS | ARGENTA DISCOVERY LIMITED (GB) | 2008-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100010034-A1 | CRTH2 ANTAGONISTS | HRH2, MDH2, HRH1 | ALDH1A1 831/4885MAPK8 1974/4885MAPK9 1431/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.